
Objective: To systematically evaluate the overall incidence and risk of adverse events (AEs) associated with pilocarpine treatment in patients with presbyopia based on randomized controlled trials (RCTs). Methods: A systematic search of CNKI, VIP, WanFang Data, PubMed, Web of Science, Scopus, and ClinicalTrials.gov was conducted from inception to January 2025 to identify RCTs evaluating AEs of pilocarpine in presbyopia patients. Pooled incidence rates were analyzed using R software (version 4.3.2) and visualized using SPSS. Relative risks (RR) were calculated using Review Manager (version 5.4). Results: Seven RCTs comprising 1825 patients were included. The overall incidence of treatment-emergent AEs (TEAEs) was 23.4% (95% CI: 16.5%-30.3%). The incidence was higher with high-concentration (1.0%-1.5%) formulations (29.3%; 95% CI: 23.8%-35.9%) compared with low-concentration (0.4%-0.5%) formulations (17.1%; 95% CI: 9.7%-26.1%). No severe AEs were reported, and the treatment discontinuation rate was low (0.6%). Headache (6.1%) and blurred vision (4.3%) were the most common systemic and ocular AEs, respectively. Pilocarpine significantly increased the risks of specific AEs: blurred vision (RR = 4.45, 95% CI: 1.97-10.06; P = 0.000 3), instillation site pain (RR = 6.42, 95% CI: 1.89-21.83; P = 0.003), visual impairment (RR = 7.86, 95% CI: 2.12-29.09; P = 0.002), eye pain/brow pain (RR = 4.19, 95% CI: 1.79-9.82; P = 0.001), eye irritation (RR = 6.96, 95% CI: 1.86-25.97; P = 0.004), headache (RR = 2.64, 95% CI: 1.81-3.83; P <0.0001), and nausea (RR = 8.85, 95% CI: 1.13-69.52; P = 0.04). Conclusions: Pilocarpine exhibits a favorable safety profile in the treatment of presbyopia, characterized by predominantly mild and transient AEs. However, it is associated with an increased risk of headache, nausea, blurred vision, eye irritation, instillation site pain, eye pain/brow pain, and visual impairment.
Ocular ultrasound plays a vital role in ocular structural imaging and disease evaluation given its noninvasiveness, real-time capabilities, and cost-effectiveness. Over the past decades, improvements in imaging resolution, device portability, and operational safety have significantly expanded its clinical applications. This review systematically summarizes the technological advancements and clinical applications of A-scan and B-scan ultrasonography, ultrasound biomicroscopy, Doppler ultrasonography, three-dimensional ultrasonography, and ultrasound elastography. Furthermore, it examines the current state of research regarding artificial intelligence (AI) in ocular ultrasound image analysis. Conventional ultrasound techniques play an important role in ocular biometry, the assessment of anterior and posterior segment structures, and the evaluation of ocular hemodynamics. Three-dimensional ultrasound and elastography have further expanded the scope of ocular imaging by enabling the assessment of spatial anatomy and tissue biomechanical properties. Driven by advances in AI, the analysis of ocular ultrasound images is gradually moving toward greater automation, quantitative assessment, and standardization. Deep learning, in particular, has shown initial promise in image segmentation, lesion identification, and quantitative analysis. Emerging techniques such as multimodal fusion, vision-language models, and spatiotemporal modeling of ultrasound video sequences offer new research directions aimed at improving diagnostic efficiency and interpretive consistency. Further efforts should focus on standardizing ocular ultrasound imaging techniques and clinically validating AI algorithms to facilitate the translation and implementation of these emerging technologies into routine clinical practice.
Aim: To investigate the clinical and multimodal imaging features of patients with choroidal osteoma (CO) and evaluate the complications related to tumor decalcification and their impact on visual prognosis. Methods: This retrospective case study included eight patients (nine eyes) diagnosed with CO at the Ophthalmology Department of Affiliated Hospital of Jining Medical University from January 2015 to December 2024. Clinical signs and multimodal imaging findings were reviewed, including fundus photography, orbital computed tomography (CT), B-scan ultrasonography, fundus fluorescein angiography (FFA), optical coherence tomography (OCT), and OCT angiography (OCTA). Tumor decalcification was identified based on fundus photography and OCT features. Complications, such as choroidal neovascularization (CNV), were assessed using FFA, OCT, and OCTA. Clinical and imaging characteristics were compared between eyes with decalcified and non-decalcified CO. Results: Among the eight patients, seven were female and one was male, with a mean age of (27.3 ± 7.5) years. CO was unilateral in seven patients and bilateral in one. All lesions were located in the posterior pole, involving the macula. Initial best-corrected visual acuity (BCVA) ranged from counting fingers at 30 cm to 1.0 (20/20). Seven eyes exhibited varying degrees of decalcification. During follow-up, one lesion showed tumor growth. BCVA remained stable in six eyes, improved from 0.4 to 1.0 without treatment in one eye, and improved and stabilized following anti-VEGF therapy in another. Complications within decalcified areas included neurosensory retinal detachment (NSRD) in four eyes, CNV in four eyes, subretinal hemorrhage in three eyes, and subretinal fluid in four eyes. Eyes with macular CNV exhibited poorer visual outcomes. Certain complications, such as NSRD and subretinal hemorrhage, resolved spontaneously without intervention. Conclusions: Tumor decalcification in CO is associated with visual impairment and secondary complications, particularly when the macula is involved or CNV develops, resulting in a poorer prognosis. Close monitoring is essential for patients with macular decalcification.
Objective: To investigate the level of illness uncertainty among parents of children with glaucoma and to provide a basis for developing targeted nursing interventions. Methods: Using a cross-sectional convenience sampling design, 199 parents (primary caregivers) of children with glaucoma were recruited from the Zhongshan Ophthalmic Center at Sun Yat-sen University between October 2023 and October 2024. Data were collected using a self-designed social demographic questionnaire, the Chinese version of the Parent's Perception of Uncertainty in Illness Scale (PPUS), the Social Support Rating Scale (SSRS), and the State-Trait Anxiety Inventory (STAI-S). Univariate analysis, Pearson correlation analysis, and multiple linear regression analysis were performed to identify the predictors of parental illness uncertainty. Results: The mean total PPUS score was 72.75 ± 11.11, slightly above the theoretical midpoint, indicating an overall moderate level. However, scores for the complexity (22.19 ± 4.15) and ambiguity (28.77 ± 6.44) dimensions were high. Parental illness uncertainty was negatively correlated with social support (r=−0.388, P<0.01) and positively correlated with state anxiety (r=0.544, P<0.01). Multiple linear regression analysis revealed that social support (β=−0.208, P=0.001), state anxiety (β=0.432, P<0.001), and severe financial burden (β=0.254, P=0.038) were independent predictors of parental illness uncertainty. Conclusions: Parents of children with glaucoma experience a moderate overall level of illness uncertainty, with notably high levels in the complexity and ambiguity dimensions. Low social support, high state anxiety, and a heavy financial burden are key contributors to elevated parental illness uncertainty. Clinical nurses should prioritize illness-related education, expand social support resources, and provide effective psychological counseling to alleviate this uncertainty, thereby improving the quality of parental care.
Objective: To systematically analyze the use of excipients in eye drops newly approved by major global regulatory agencies over the past two decades, and to provide a basis for designing highly effective and well-tolerated ophthalmic formulations. Methods: Data were collected on new drugs approved by the pharmaceutical regulatory authorities of China, the United States, the European Union, and Japan between May 2004 and May 2025. The use of key excipients in 124 novel eye drops, including pH-adjusting agents, viscosity-enhancing agents, preservatives, stabilizers, solubilizers, and humectants, was statistically analyzed. Results: Of the 124 eye drops, 96.0% contained pH-adjusting agents, with phosphate, borate, and citrate being the most commonly used buffer systems. Viscosity modifiers were incorporated in 39.5% of the products, predominantly carbomers and hypromellose. Furthermore, 54.8% contained added chemical preservatives. Sodium chloride was the primary tonicity agent, while edetate disodium was the most commonly used stabilizer. Conclusions: The strategic use of key excipients such as pH-adjusting agents, viscosity modifiers, preservatives, stabilizers, and solubilizers, combined with intelligent drug delivery systems when appropriate, represents a core strategy in ophthalmic solution development to enhance drug bioavailability and ocular safety. More, the selection of these excipients distinct usage patterns.